REG-PanGenomic Health Inc: PanGenomic Health Announces Withdrawal from AQSE

Pangenomic HealthAnnouncement

19/02/2024 08:47

PanGenomic Health Announces Withdrawal from AQSE

 

Vancouver, British Columbia, Canada, 19 February 2024 - PanGenomic Health Inc.
("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA) announces its
intention to withdraw the Company's Class A Common Shares ("Shares") from the
Aquis Stock Exchange Growth Market ("AQSE").

 

Pursuant to the AQSE Access Rulebook, the Company is required to give 20
business days' notice of its intention to withdraw from trading on AQSE.
Therefore, trading in the Shares will cease at 4:30 pm, UK time, on 15 March
2024.

 

The Shares will continue to trade on the Canadian Securities Exchange under
the symbol, "NARA", and the Frankfurt, Berlin, Hamburg, Stuttgart and Munich
Stock Exchanges under the symbol, "LL30".

 

The directors of the Company have taken this decision in light of the limited
trading of the Shares on the Access Market segment of AQSE since the Company's
admission to the AQSE.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

The directors of PanGenomic Health take responsibility for this announcement.

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalized, evidence-based information about
natural treatments. The Company's initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

 

For more information, please contact:

 

Jerry Lai, Investor Relations   Novum Securities Limited, AQSE Corporate
Adviser

PanGenomic Health Inc.   David Coffman/ George Duxberry

+1 778 743 4642    +44 (0)207 399 9400

ir@pangenomic.com     

 

This news release includes certain statements that may be deemed
"forward-looking statements", including statements respecting the services to
be provided by PanGenomic Health and the consideration to be paid to
PanGenomic Health. The use of any of the words "anticipate", "continue",
"estimate", "expect", "may", "will", "would", "project", "should", "believe"
and similar expressions are intended to identify forward looking statements.
Although PanGenomic Health believes that the expectations and assumptions on
which the forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because PanGenomic
Health can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by their very
nature they involve inherent risks and uncertainties. These statements speak
only as of the date of this News Release. Actual results could differ
materially from those currently anticipated due to a number of factors and
risks including various risk factors discussed in PanGenomic Health's
disclosure documents which can be found under PanGenomic Health's profile on
www.sedarplus.ca.

 

The Canadian Securities Exchange has neither approved nor disapproved the
information contained herein and does not accept responsibility for the
adequacy or accuracy of this news release.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved